Phase i & phase i/II clinical trials for treatment of covid-19 associated ards by AV-001, a novel therapeutic targeting vascular endothelium
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2110834
- Recipient
-
Vasomune Therapeutics Inc. UEI ETXLYBADLEM7
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $6,354,825
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Originally
- Place of performance
- 2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $6,354,825 |
Quick answers
Who received award W81XWH2110834?
W81XWH2110834 was awarded to Vasomune Therapeutics Inc. by Defense Health Agency (Department of Defense) on September 1, 2021.
How much is award W81XWH2110834 worth?
$6,354,825 has been obligated on W81XWH2110834.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award